Protocol Paxlovid for Treatment of Long Covid (STOP-PASC), 2022, Singh et al, Stanford University - recruitment stopped June 2023

From the Protocol:

Paxlovid for Treatment of Long Covid (STOP-PASC)
Brief Summary:
The purpose of this study is to compare whether being treated with Paxlovid (nirmatrelvir plus ritonavir) for 15 days works better than being treated with placebo (plus ritonavir) to reduce severe symptoms of Long Covid (the placebo does not have any active drug).

Participants will have 5 planned visits to the study clinic over 15 weeks and will take the drug (or placebo) for the first 15 days.

This study uses the term post-acute sequelae of SARS-CoV-2 (PASC), which is another name for "Long Covid."
Study Design

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Selective Trial Of Paxlovid for PASC (STOP-PASC): Randomized Double-Blind Placebo-Controlled Pilot Trial of Paxlovid for the Treatment of PASC
Actual Study Start Date : November 8, 2022
Estimated Primary Completion Date : October 2023
Estimated Study Completion Date : November 2023

 

There's a much bigger phase 3 study as part of RECOVER being run by Duke University. See this thread:
RECOVER Treatment Study: Paxlovid for long Covid

There's also the Iwasaki (Yale) trial. See this thread.
Protocol A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir [Paxlovid] in Adults With Long COVID, 2023, Iwasaki el al.

I wonder whether the early stop on this Stanford trial will impact those other 2 trials.

 

That's what the Medpage article seems to indicate from the bit Kalliope quoted.

 

The article from medpage is on this archive site:
https://archive.fo/EWHGn